Intratympanic Dexamethasone Delivery versus Placebo in Intractable Meniere Disease

Background: Numerous treatments strategies were used for Meniere disease (MD). In this study, we aimed to compare the efficacy of intratympanic dexamethasone versus intratympanic placebo in intractable MD.Methods: This was a single-blinded randomized clinical trial. All patients with Intractable MD underwent ventilation tube insertion into tympanic membrane and were randomly allocated to two groups of 18-patients. The patients of the first group used dexamethasone base drop (placebo) every other day, the second group used dexamethasone drop for 3 months, and all patients were followed for 12 months.Results: Control of vertigo and tinnitus with dexamethasone was more than the placebo, but there was no statistically significance difference between two groups (P > 0.05). Hearing function improvement and aural fullness resolution were higher in the placebo group, but there was no statistically significance difference, too (P > 0.05). Vertigo control in dexamethasone group in our study ranged from 72.2% to 83.3% of patients at different intervals. These figures ranged from 66.6% to 83.3% in placebo group. The highest rate of hearing function improvement in our study was 27.7% in placebo group. Tinnitus also followed the same pattern as hearing function.Conclusions: Intratympanic dexamethasone for MD is very satisfactory if medical treatment fails with good vertigo control and no risk to hearing.© 2014 Tehran University of Medical Sciences. All rights reserved.Citation: Borghei P, Sadeghian E, Hasanzadeh F, Emami H. Intratympanic Dexamethasone Delivery versus Placebo in Intractable Meniere Disease. Acad J Surg, 2016; 3(3-4): 58-62.

کلیدواژه ها:

Meniere disease ، Intratympanic injection ، Dexamethasone ، Placebos